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EXECUTIVE SUMMARY 
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Introduction 
Massachusetts is experiencing both an increase in pharmacy expenditures and a decrease in resources to cover 
these expenditures.  Implementation of measures to better manage medications, including controlling and limiting 
medication waste, is an important priority.  Medication waste can include the actual physical destruction and 
disposal of unused pharmaceuticals.  Medication waste also occurs when a drug therapy is ineffective and does not 
benefit the patient.  This may be due to the prescribing and consumption of medications that are therapeutically 
inappropriate or unnecessary, or prescribed at sub-therapeutic doses or for inadequate periods of time.   
On August 14, 2002, the Massachusetts Legislature passed into law, Chapter 282 of the Acts of 2002 (Attachment 
1), An Act Reducing Medication Waste in Certain Licensed Facilities.  Pursuant to the Act, the Department of Public 
Health (DPH), in conjunction with the Board of Registration in Pharmacy (BRP) and the Division of Medical 
Assistance (DMA), convened the Medication Management Task Force to review and recommend methods to reduce 
medication waste in facilities licensed by the DPH, Department of Mental Health (DMH) and the Department of 
Corrections (DOC).  These include Long Term Care Facilities (LTCFs) , certain licensed residential facilities and 
correctional institutions, herein referred to as “residential and correctional facilities.”  The Task Force determined 
that methods must be practical, flexible and economical for integration into the drug therapy for today’s patients  
The challenge of medication management in the facilities mentioned in the legislation depends on the type of 
patient or resident.  In general, LTCF residents today are no longer individuals who have lost the capacity for self-
care due to chronic illness and advanced age but are individuals with temporary needs for skilled nursing care 
because their capacity for self-care is on hold due to trauma or illness.  The State Office of Pharmacy Services 
(SOPS) provides pharmaceutical care for patients in the care of DMH and the Department of Mental Retardation 
(DMR), in state hospitals, and inmates within correctional facilities, populations that are more stable than those at 
LTCFs.  Accordingly, in these different settings, approaches to medication management may be similar; however, 
individual methods recommended by the Task Force may not be applicable across all of the settings. 
 
Agency Collaboration 
Prior to enactment of Chapter 282 of the Acts of 2002, DPH, BRP and DMA had begun to discuss medication 
management issues of common concern.  The agencies began meeting in the fall of 2001 and focused first on the 
return of unused medications for redispensing.  Based on results of a pilot project conducted in the mid 1990s, 
DPH and BRP had determined that unit-dose packaged and certain unsealed multi-dose packages could be allowed 
to be returned for redispensing.  In spring, 2002, DPH issued guidelines and policies that allowed for the return of 
certain medications in unit-dose packaging from LTCFs.  Concurrently, BRP issued a policy for pharmacists 
regarding the safe redispensing of medications returned from LTCFs.  With these policies and guidelines in place, 
DMA proceeded to promulgate and implement regulations for the mandatory return of eight of the costliest drugs 
(based on volume) dispensed to residents in LTCFs.  To facilitate the implementation of this regulation, DMA 
produced best practices for LTCFs and pharmacies, a training curriculum for LTCFs, and a start-up implementation 
support center.  All of the agencies’ activities involved collaborating with industry and other interested parties prior 
to the implementation of policies and regulations. 
 
Process 
Gathering information from the literature, other states, local experts and stakeholders.   
The Task Force conducted two surveys.  The BRP surveyed states on the use of automated pharmacy systems. 
(Attachment 2)  The DPH and the DMA surveyed equivalent public health and Medicaid assistance programs in 
other states to gather data on reimbursements and methods used to reduce medication waste.  (Attachments 3 
and 4)  A trade publication was also referenced for comparison of states. (Attachment 5) 
A stakeholder conference was held on October 28, 2002.  Invitees were representatives of the agencies and 
professional organizations listed in section (b) of Chapter 282 and other stakeholders. (Attachment 6)  Three topic 
areas -- technology, standards and economics -- were chosen as foci for the conference to elicit as much input 
from attendees as possible regarding the issues put forth by the legislature.  During the program, the group 
identified methods to reduce medication waste.  
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Presentation of recommended methods. 
Below is a chart of the Task Force’s recommended methods to reduce medication waste.  The Task Force did not 
rate or rank the methods because no data quantifying the reduction in waste on which to base such an assessment 
was found in the literature or the surveys.  It was beyond the scope of the Task Force to examine potential costs 
to implement these methods. 
One additional recommendation made by the conferees, with which the agencies concur, is to plan for 
demonstration projects of adopted methods.  The legislature intended that recommended methods not negatively 
affect other areas of the health care delivery system.  Demonstration projects to study recommended methods 
would provide the data needed to answer this charge. 
 
Chart of Methods Recommended To Reduce Medication Waste 
Method 
 
Regulatory/Statutory 
Changes Required 
Status Require Involvement of 
Agencies Outside of the 
Task Force 
Use of Medical Practice 
Guidelines 
None Being done now on a limited 
basis 
(DMA reviews records for 
poly-pharmacy) 
None 
Prescription Ordering  
(Initial and Refills) 
None Being done now on a limited 
basis 
None 
Academic or Counter 
Detailing 
 
None Being done now in DOC; 
DMA is beginning program 
None 
Collaborative Practice Yes 
(S. 630 and S. 573)  
Not allowed at present Board of Registration  
in Medicine 
Formularies/Drug Lists  None Used by State Office of 
Pharmacy Services; DMA 
utilizes the MassHealth Drug 
List 
None 
Therapeutic Interchange None Some application in 
restricted settings 
US Drug Enforcement 
Administration 
Prior Authorization None Being done now by DMA None 
Automated Pharmacy 
System 
None Not being done U.S. Drug Enforcement 
Administration 
Return for Redispensing None Being done now None 
Release Medication With 
Patient Upon Discharge 
None Being done now None 
 
BACKGROUND 
 
Agencies’ Missions Regarding Reduction of Medication Waste 
The Department of Public Health, through its Drug Control Program, ensures access to safe and effective 
pharmaceutical care and protects consumers against unsafe practices in the handling and distribution of 
pharmaceuticals.  The Department has statutory responsibility to set standards for the distribution of 
pharmaceuticals by health care facilities and community programs. 
 
The Board of Registration in Pharmacy in the Department of Public Health establishes standards for and oversees 
the provision of quality pharmaceutical care through regulation of the practice of pharmacy and the distribution of 
prescription drugs and devices.   
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The Division of Medical Assistance strives to ensure the utilization of safe and cost-effective drugs, reduce waste 
and purchase pharmaceuticals at the lowest price possible. 
 
Task Force Project Leaders 
Task Force project leaders are for DPH, Adèle Audet; BRP, Charles Young and DMA, Rita Sevier.  Tim MacIntyre, 
represents DPH, Division of Health Care Quality.  
 
Addressing Medication Management Prior to Chapter 282 
Special Project: Dispensing of Unit Dose Medications in LTCFs 
In 1996, DPH presented a special report on the dispensing of unit dose medications in LTCFs to the Joint 
Committee on Health Care.  This report showed that the use of unit-dose packaging as a method for medication 
distribution and administration in LTCFs as well as return for redispensing could be a safe and effective means to 
reduce medication waste.  
 
DMA, BRP and DPH Collaboration for Return for Redispensing in LTCFs 
In fall 2001, DPH, BRP and DMA, lead by DMA’s Unit Dose/Return for Redispensing Project, began to discuss 
medication waste and how methods of medication management could address the issue.  The term “medication 
management” includes, but is not limited to, the following activities: ordering, dispensing, administering, labeling, 
security, storage and disposal of drugs, counseling, drug utilization review, stop orders, and emergency and non-
routine dispensing procedures.  According to M.G.L. 111 §25I (Attachment 7), certain medications dispensed to 
individual patients may be returned for credit to the pharmacy from which the medication was dispensed.  In 
winter 2001-2002, the agencies held meetings with stakeholder groups to discuss proposed regulations, guidelines 
and policies for implementing M.G.L. c. 111 §25I and allowing the return of prescription drugs dispensed to 
residents of LTCFs.  
In April 2002, the DPH and BRP finalized their policy documents for implementing M.G.L. c. 111 §25I.  DPH issued 
“Guidelines for Use of Unit-Dose Packaging for the Management and Administration of Pharmaceuticals in Long 
Term Care Facilities” and the “Policy on Return for Redispensing of Medications from Long Term Care Facilities”. 
(Attachments 8 and 9)  These established the standards under which LTCFs could return certain unused Schedule 
VI unit-dose packaged and over-the counter medications to pharmacies.  The BRP issued Policy PH 2002 - 01, 
“Policy on Return for Redispensing of Medication from Long Term Care Facilities.” (Attachment 10)  This policy 
allowed pharmacies to accept medications, dispensed to individual patients in LTCFs, for return.  Simultaneously, 
members of DMA’s Unit-Dose Return and Redispense Project met with stakeholders to discuss proposed regulations 
that would require LTCFs to return eight of the most costly drugs (Depakote, Neurontin, Paxil, Prevacid, Remeron, 
Risperdal, Zoloft and Zyprexa, based on volume) representing 34 total drug products/dosage forms.  The list of 
drugs can be modified quickly by DMA, as necessary.  Promulgation and implementation of DMA’s regulations in 
June 2002 (Transmittal Letters NF-43 and PHM-45, Attachments 11 and 12) included regulations and best practices 
for LTCFs and pharmacies, a training curriculum for LTCFs and start-up implementation support.  An advisory 
group continues to meet with DMA representatives to address areas of managing waste, pharmacy costs and 
quality of care issues in nursing facilities.  
 
DOC Return for Redispensing of Medications Dispensed to Inmates 
In July 2001 the DOC and the State Office of Pharmacy Services (SOPS) contracted with a vendor, McKesson, for 
equipment and software programs to repackage selected bulk solid oral dosage forms into unit-dose containers.  
The SOPS determines which drugs will be returned for redispensing based on cost impact and waste data. 
(Attachment 13)  Adding or deleting drugs from this list is easier than the adding or deleting from the DMA list 
since this is a closed system and the list is not in regulation.  This facilitates a quicker response to changes in 
population, prescribing practice or drug cost and availability.  The Director of the State Office of Pharmacy Services 
says that return for redispensing to date has produced saving of approximately $300,000 per year.  The initial 
expense for equipment and software was $65,000. 
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REPORT 
 
Introduction  
Massachusetts is experiencing both an increase in pharmacy expenditures and a decrease in resources to cover 
these expenditures.  Implementation of measures to control and limit medication waste is an important priority.  
Medication waste can include the actual physical destruction and disposal of pharmaceuticals, medications that are 
therapeutically inappropriate or unnecessary and do not benefit the patient, and medications that are prescribed at 
sub-therapeutic doses or for inadequate periods of time.  
On August 14, 2002, Chapter 282 of the Acts of 2002, An Act Reducing Medication Waste in Certain Licensed 
Facilities, was enacted.  Pursuant to Act, the Department of Public Health (DPH), in conjunction with the Board of 
Registration in Pharmacy (BRP) and the Division of Medical Assistance (DMA) convened the Medication 
Management Task Force to review and recommend methods to reduce medication waste in facilities licensed by 
the DPH, Department of Mental Health (DMH) and the Department of Corrections (DOC).  
The Task Force determined that methods to reduce waste should not impose unreasonable costs on the health 
care delivery system, patient outcomes should be maintained or improved, and solutions should be found that are 
practical, flexible and economical for integration into the drug therapy of patients.   
Resources for consultation were listed in Chapter 282  Section 1 (b).  The Act stated that the Task Force shall 
consult the Boards of Registration in Medicine and Nursing, the Department of Mental Health and the Department 
of Corrections.  In addition, the lead agencies could approach other resources for consultation beyond the expertise 
of Task Force members or listed consultants.  
 
Process 
The Task Force’s first meeting was held on September 11, 2002.  The Task Force established a group 
understanding of the statutory language (current technology, standards and reimbursement mechanisms for 
dispensing and distribution medications to facilities, other states’ requirements for limiting prescription drug waste 
and any cost savings realized; the commonwealth’s standards for return and re-dispensing of patient specific 
schedule VI prescription drugs and possible incentive mechanisms to prevent the creation of prescription drug 
waste) and the meaning of “without imposing unreasonable costs on the health care delivery system.”  Assessing 
the financial impact of any changes in pharmaceutical care (the field of pharmacoeconomics) would require 
consultation with an expert in that area of study.  The Task Force recognized that any discussions of 
reimbursement or incentive mechanisms were outside the jurisdiction of the Task Force. 
Literature searches were performed, and Task Force members and staff at the three lead agencies contacted other 
states.  The Task Force conducted two surveys of other states: the BRP obtained information from 28 states on the 
use of automated dispensing machines in LTCFs and whether pharmacies or pharmacy departments were allowed 
to exist within LTCFs; and the DPH and DMA surveyed other states’ public health and Medicaid assistance programs 
and Boards of Pharmacy. (see attachments 2, 3 and 4 for survey questions and results) 
A stakeholder conference was held on October 28, 2002.  The Task Force engaged Richard Gleason, a conference 
facilitator and adult educator from the Division of Professional Licensure, who assisted in the general planning of 
the meeting and the format for the invited experts and the small workgroup exercises.  Three topic areas were 
chosen as foci for the conference; technology, standards, and economics.  Stephen Feldman, President of the 
American Society of Consultant Pharmacists spoke about pharmacy technology, Robert Paone, member of the 
Board of Registration in Pharmacy presented on regulations, laws and protocols, and Judith Barr, Associate 
Professor of Pharmacy and Director of the National Education and Research Center for Outcomes Assessment at 
Northeastern University, discussed economics and evaluations. (see participant list, Attachment 6). 
 
Facility Overview 
Long Term Care Facilities 
In general, medication waste is the result of out-of-date or sub-optimal drug therapies, inefficient medication 
ordering procedures, poor discharge planning and other factors.  According to the 1999 National Nursing Home 
Survey, 94.1% of all residents received “prescribed and non-prescribed” medicines in the immediate 30 days prior 
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to record review1.  High utilization of prescription medications underscores the need to adopt safe and effective 
measures to address medication waste.  
Medication waste is also the result of non-response to changes in the patient populations to more acute patients 
and the higher patient turnover seen in Massachusetts LTCFs today 2.  In the United States the percentage of 
nursing home discharges for residents whose length of stay was 3 months or less was 68.3%.  In addition to being 
discharged to a residence, other events that can be anticipated during drug therapy could include discharge for 
admittance to hospital with return to LTCF, discontinuation of an antibiotic, increase or decrease of medication 
dosage depending on patient response and discontinuance of a medication that is causing side effects and loss of 
life.   
A study published in 1996 examined the reasons for medication destruction and calculated that the cost of 
medication waste was $0.15 per patient day and the percentage of drug waste was 6.7% of the cost of 
medications dispensed in Massachusetts LTCFs3.  According to DMA the total dollars in LTCFs in FY 2002 was 
$116,238,674.00 for medications in LTCFs. 
Only by using a combination of improvements in existing functions and introduction of new practices can 
medication waste, caused by multiple factors be addressed.  In general, the LTCF resident is no longer an 
individual who has lost the capacity for self-care due to chronic illness treated with simple medication regimens but 
is more typically an individual, with an acute illness treated with a complex medication regimen, with temporary 
needs for skilled nursing care.  The reduction of medication waste in LTCFs will come from implementing practical 
technological and medical solutions that integrate the hundreds of new therapies in a population of the elderly 
whose capacity for self-care is not gone but on hold due to trauma or illness and a population of short term stay 
patients.   
 
Department of Corrections and Departments of Mental Health and Mental Retardation 
For purposes of this report, selected segments of the Departments of Corrections, Mental Health and Mental 
Retardation are considered “closed systems” because all aspects of pharmaceutical care are controlled by the State 
Office of Pharmacy Services either directly or through contracts.  Closed systems have a measure of autonomy that 
is not experienced by pharmacies or LTCFs caring for residents in the community.  Within closed, not-for-profit 
systems the challenges of medication management are much less complex than in open, for-profit systems.  
Sites included in these systems are certain correctional facilities (certain MA Correctional Institution sites, houses of 
correction and county jails) and state hospitals.  Within the DOC there are approximately 5100 inmates receiving 
medication.  The population is relatively stable with respect to residency and disease state.   
Clients of DMH and DMR in certain group homes and other independent living arrangements are considered to be 
living in private residences and disposal of their medications are not subject to medication return policies. 
 
Limitations of Review and Recommendations 
There is limited documentation of actual waste in LTCFs that can be used to determine the extent of the problem 
or to establish a baseline to measure a reduction in waste.  Current and valid data are not available to compare 
medication waste from past practices with the changes after implementation of most recommendations to reduce 
waste.  Further, any data on cost savings methods may only be for one population set and cannot be extrapolated 
to the entire LTCF, DOC or DMH populations.   
As individual agencies and collaborators on the unit-dose/ return for redispensing project, the Task Force has seen 
from previous work that there is no single solution that can address rising pharmaceutical costs.  The Task Force 
has not rated the recommended methods because of the lack of data quantifying the reduction in waste on which 
to make such recommendations.  Furthermore, the financial benefit, whether waste reduction, cost savings or a 
combination of methods would depend on the extent of the individual facility’s ability to utilize the method(s).  
Assessment tools must be developed to determine if the recommended methods can reduce waste and not impose 
unreasonable costs on the health care delivery system.   
Time and resource constraints limited the robustness of the DMA and DPH surveys. However the BRP survey 
(Attachment 2) and the National Pharmaceutical Council, “Pharmaceutical Benefits Under State Medicaid Assistance 
1 Vital and Health Statistics Series 13, Number 152 The National Nursing Home Survey: 1999 Summary, Data From the National Health Care Survey, Table 21 
2 Massachusetts Extended Care Federation, January 31, 2002, letter in response to the Final Drat Report to the Health Care Task Force 
3 Paone RP, Vogenberg FR,et.al. Medicaion Destruction and Waste Measurement and Management in Longterm Care Facilities. Consult Pharm 1996; 11:32-40 
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Programs, Pharmacy Payment and Patient Cost Sharing” chart (Attachment 5) provided excellent information that 
can be referenced in the future.  Stakeholders are expectedly most interested in reimbursement issues and 
incentive programs.  The Task Force was not able to fully address the financial issues, in part because not all the 
necessary parties participated.  In addition, the cost impact of specific recommendations cannot be immediately 
assessed. 
 
Task Force Recommendations 
The recommended methods for improving medication management are described in the paragraphs below.  
Following the description is the recommendation for implementation of the method.  Key questions used in 
determining whether to recommend a method include: (1) Has this method shown a positive impact on medication 
waste reduction in other states or patient care settings; (2) Would this method require start-up monies for 
equipment or staffing; (3) Would this method require a statutory or regulatory change; and (4) Can this method be 
employed now without negatively impacting the health care delivery system? 
It is important to note that recommended methods adopted by facilities must maintain or improve patient care.  
The Task Force will continue working with providers to address quality of care issues. 
 
Use of Medical Practice Guidelines
 
Evidence-based medicine guidelines, (e.g., from the Cochrane Library or National Guideline Clearinghouse, 
Attachment 14), approved compendial standards and disease state review articles in peer-reviewed literature are 
available to prescribers and pharmacists.  These guidelines or standards can be used by prescribers and 
pharmacists to assess current drug treatment for therapeutic appropriateness, overutilization and underutilization, 
appropriate use of generic drug products or less expensive first line drug therapies, therapeutic duplication, drug-
disease contraindications and drug-drug interactions in order to improve the quality of care and to conserve 
program funds or individual expenditures.   
This method may require staff time to choose the most beneficial guideline for the patient population and for the 
clear communication of how the guideline will be used in the facility. No statutory or regulatory changes are 
required.  Prescribers and pharmacists using guidelines and sound therapeutic judgment can treat patients without 
negatively impacting the health care delivery system.   
Currently MassHealth reviews patient records to identify individuals who receive multiple medications. In cases of 
overutilization of medications, letters of inquiry are sent to prescribers.  
 
Recommendation: The Task Force recommends that prescribers and pharmacists refer to standards and 
guidelines from evidence based medicine to limit medication mismanagement and waste that can result from sub-
optimal, inappropriate or duplicative drug therapy.   
Regulatory/Statutory Changes Required: None 
Status: Being done now on a limited basis by DMA in polypharmacy utilization reviews. 
Requires Involvement of Agencies Outside of Task Force: No 
 
 
Prescription Ordering and Delivery
 
When DMA promulgated its regulations on the return for redispensing of unused medications it also published best 
practice guidelines for LTCFs and LTCF provider pharmacies.  Some of the best practices for medication ordering 
are noted below with suggestions for their implementation.   
Prescriptions for drug products that are new therapies for a patient should be ordered in limited quantities.  The 
supply should be just sufficient in quantity to allow an adequate trial period for assessment of patient response.  If 
the therapy is beneficial, then the prescription can be reordered for a larger quantity.  The prescription can be 
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modified if there are dose related problems or side effects.  Finally, the medication can be discontinued if the 
therapy is not successful or not tolerated.  Limiting the quantities of first time drug therapies, or issuing starter 
doses, can decrease prescription drug waste if the therapy is discontinued shortly after it is initiated.   
Prescription refill orders can be optimized to prevent dispensing too early or ordering too late.  Dispensing too early 
can cause accumulation of medications that may be discontinued due to change in therapy, discharge or death.  
Ordering too late may mean that a patient's medications must be delivered separately from the routine delivery 
incurring extra costs.  It has also been suggested that refills of maintenance medications for chronic conditions be 
ordered in staggered cycles.  This method can decrease the possibility of wasting large quantities of medications 
that were ordered shortly before discharge or death.  
The Task Force agrees with DMA’s best practices.  Professional associations may choose to compile information 
and experience with new methods of prescription ordering, refilling or delivery systems as implemented by LTCFs 
and pharmacies.  Methods could then be reviewed for ease of implementation, any effect on staff workload, safety 
and cost savings by other facilities.   
 
Recommendation: The Task Force recommends that prescribers, facilities and pharmacies re-examine current 
prescripition ordering, refilling and delivery systems to develop reasonable and cost-effective improvements.   
Regulatory/Statutory Changes Required: None 
Status: Being done now on a limited basis for different patient populations. DMA believes compliance with their 
best practices is high in LTCFs.    
Requires Involvement of Agencies Outside of Task Force: No 
 
 
Academic or Counter Detailing
 
Pharmaceutical companies employ salespeople to market drug products by calling upon prescribers and discussing 
their benefits, improvements or uniqueness of the product.  One term for this activity is “product detailing”.  
Government agencies and non-government providers responsible for managing prescription drug benefits are now 
performing a similar activity, with a different goal, called “academic” or “counter” detailing.  These agencies and 
providers employ clinical pharmacists who provide educational outreach to increase cost effective prescribing.  One 
well-known current topic of academic detailing is the effort to decrease inappropriate or overprescribing of 
antibiotics.   
Last year the Department of Corrections reported a cost savings (avoidance) of $350,000 through the interventions 
of a clinical pharmacist at SOPS.  The projected cost savings this year is expected to be $500,000.  The cost of new 
therapies is increasing sharply at the same time pressure is escalating to control health care costs. A small but 
important body of research and practice has begun to emerge based on the concept of academic detailing that 
may present a rational response to these pressures.4  West Virginia has begun using academic detailing for the 
Public Employees Insurance Program.  DMA has recently hired a clinical pharmacist to begin a program of 
academic detailing.  LTCFs and provider pharmacies could do the same.   
Start-up costs can include time for research, development of materials for presentations to prescribers and the 
actual visits to facilities and prescribers.  Each agency in the Task Force works with the local colleges of pharmacy 
in maintaining intern programs for Pharm.D. candidates.  Academic detailing could be an area for agency 
collaboration with the colleges. 
 
Recommendation: The Task Force recommends that agencies and providers use academic detailing to increase 
cost effective prescribing. 
Regulatory/Statutory Changes Required: None 
Status: Being done now in DOC and DMA is beginning a program.  
Requires Involvement of Agencies Outside of Task Force: No 
                                                     
4 Soumerai SB, Avorn J, Principles of Educational Outreach (‘Academic Detailing’) to Improve Clinical Decisiojn Making. JAMA January 26, 1990 Vol 263, No.4 549-556 
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Collaborative Practice
 
Collaborative drug therapy management (collaborative practice) is a key component of today’s patient care.  
Collaborative practice is pharmaceutical care provided by a qualified pharmacist who has a written agreement with 
a physician and requires protocols that are developed and agreed upon by the pharmacist and physician.  Activities 
determined by the protocol can include but are not limited to: initiating, modifying and monitoring a patient’s drug 
therapy; ordering or performing laboratory and related tests, assessing patient response to therapy; and 
administering medications.   
The pharmacist’s involvement in developing and maintaining protocols is advantageous in drug product selection, 
assessment of side effects (for example a trial of a lower dose of an antihypertensive rather than adding a 
medication for dizziness, a possible side-effect of the antihypertensive), monitoring laboratory and other tests and 
continual review of new products approved by the Federal Food and Drug Administration (generic or brand-name).  
It has been shown that when pharmacists are involved in the patient’s drug therapy in selected settings there can 
be a decrease the number of adverse drug events5.  Costs related to adverse drug events depend on the 
intervention required which can range from hospital admittance to discontinuing the causative medication.   
Collaborative practice for drug therapy management is utilized by the Veteran’s Administration and in 38 states.  
Legislative and/or regulatory actions would be required to fully integrate the pharmacist’s expertise into drug 
therapy management in collaborative practice.   
 
Recommendation: The Task Force recommends pharmacist collaborative practice as a method to improve 
medication management and decrease medication waste. 
Regulatory/Statutory Changes Required: Two bills have been filed, S. 630 and S. 573.    
Status:  Not allowed at present. 
Requires Involvement of Agencies Outside of Task Force: Yes, Board of Registration in Medicine 
 
 
Formularies/Drug Lists 
 
Formularies are lists that direct drug product choices to those products that are determined to be the most 
beneficial for a group of patients.  Formularies are developed by committees, usually known as Pharmacy and 
Therapeutics (P and T) Committees.  In selecting a drug product for inclusion on a formulary, members of the P 
and T committee, or equivalent, (pharmacists, prescribers, medical directors and others) review journal articles, 
clinical experience within the healthcare setting, and other sources of data.  The P and T committee provides 
continual review and oversight of the formulary.  Cost and availability can be factors governing choice when two or 
more drug products are considered to be equivalent with respect to effectiveness and side effects. Formularies may 
also establish guidelines or policies for the use of a particular drug product or therapeutic class of drugs.  
Hospitals and managed care organizations utilize formularies.  Limiting the drug products to well-chosen agents 
can be cost efficient and provides standardization of therapy.  The Department of Veteran’s Affairs, Veteran’s 
Health Administration manages a national drug formulary.  In Massachusetts the State Office of Pharmacy Services 
uses a formulary approved by the state P and T committee.  This formulary is the basis for agency (DOC, DMH, 
DMR) specific formularies and facility (hospitals, clinics) specific formularies within the agency.  The Medicaid 
programs in some states are involved in or are examining the use of formularies or preferred drugs lists.6     
The aforementioned facilities and organizations are closed systems.  However, LTCFs and the provider pharmacies 
are open systems and in an open system more careful consideration must be given to the operational aspects of 
formularies for drug product selection.  For MassHealth patients in LTCFs, the LTCF must use the MassHealth Drug 
List.  Nursing facilities use the formulary of the insurer that insures the patient, MassHealth being the payor of last 
resort. 
                                                     
5 Leapp LL, Cullen DJ, Clapp MD, et.al. Pharmacist Participation on Physician Rounds and Adverse Drug Events in the Intensive Care Unit JAMA 1999;282:267-270. 
6 Kaiser Commission on Medicaid and the Uninsured, States Strive to Limit Medicaid Expenditures for Prescribed Drugs, February 2002 
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MassHealth has chosen not to develop a formulary, per se, which would impose certain requirements on the 
Medicaid program.  The DMA created the MassHealth Drug List (MHDL) to communicate many of the pharmacy 
requirements of the Medicaid program.  While not a formulary, the MHDL has features in common with formularies 
or preferred drug lists.  However, there is more latitude that permits the use of additional drug utilization 
management techniques that help DMA fulfill it’s mission to provide clinically appropriate and fiscally sound drug 
therapy.  Since most of the patients in LTCFs are on Medicaid, the MHDL is the prevailing pharmacy management 
tool in that setting. 
In addition, a study on the pharmacoeconomic impact of implementation of a formulary in the residential and 
correctional facilities on patient outcomes should be performed.  Additional studies are needed of the impact of the 
MHDL on LTCFs.  These studies could be used to determine if the use of a formulary or drug list could result in 
costs to other areas of health care delivery.   
 
Recommendation: The Task Force recommends consideration of the use of formularies or an equivalent 
management tool, where safe and appropriate as determined by facility staff, provider pharmacy staff, consultant 
pharmacists and prescribers. 
Regulatory/Statutory Changes Required: None 
Status: Formulary used by the State Office of Pharmacy Services; DMA uses MHDL. 
Requires Involvement of Agencies Outside of Task Force: No 
 
 
Therapeutic Interchange
 
Within a single therapeutic class there may be multiple drugs that are chemically similar and produce similar 
therapeutic results.  An example of a therapeutic class is the “statins”, blood lipid lowering agents.  Some drugs in 
this class are lovastatin, simvastatin and pravastatin.  Therapeutic interchange would mean, for example, that 
lovastatin is dispensed when pravastatin was ordered.  The concept of therapeutic interchange is not new.  Health 
care facilities utilize therapeutic interchange to prevent duplication of cost and inventory as newly approved drugs 
expand the choices in a therapeutic class.  Drugs chosen must not only produce similar beneficial results but 
possess equivalent (or better) safety and side-effect profiles.  Therapeutic interchange would occur after facility 
staff, provider pharmacy staff, or consultant pharmacists and prescribers had determined the conditions governing 
the interchange.  While sufficient authority exists to implement therapeutic interchange for Schedule VI drug 
products, clarification of federal regulations would be necessary regarding limitations on the drug products in 
federal Schedules II - VI.  
 
Recommendation: The Task Force recommends consideration of therapeutic interchange that is determined 
appropriate by facility staff, provider pharmacy staff, or consultant pharmacists and prescribers. 
Regulatory/Statutory Changes Required: None. 
Status: Some application in restricted settings, e.g. hospitals or third parties.    
Requires Involvement of Agencies Outside of Task Force: Yes, U.S. Drug Enforcement Administration for 
drug products in Schedules II - V. 
 
 
Prior Authorization
 
Prior authorization is a request from either a prescriber or a provider to the payer for approval to dispense and bill 
for a prescribed medication.  The reasons medications may require prior authorization include but are not limited to 
known risks for serious side effects, limited success rates, or determination of medical necessity.  Prior 
authorization allows the agency to review an individual’s drug therapy to weigh benefits vs. risk or cost.  
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Identification of drug products requiring prior authorization may be through inclusion in a formulary.  DMA uses 
prior authorization as a method to manage the pharmacy benefit and reduce drug costs in lieu of a formulary.  The 
drug products are listed in the DMA MassHealth Drug List.  The Task Force recognizes the potential of a program of 
prior authorization to reduce medication waste.  Start-up costs for an expanded program could include training and 
software changes in billing programs among others. 
 
Recommendation: The Task Force recommends continued use of prior authorization. 
Regulatory/Statutory Changes Required: None 
Status: Being done now by DMA. 
Requires Involvement of Agencies Outside of Task Force: No 
 
 
Automated Pharmacy Systems
 
Automated pharmacy systems (APS) vary depending on the facility and the population served.  Automated 
processes can include, medication order entry into a computer, packaging of unit-dose medications and dispensing 
a unit-dose packaged medication from a storage cabinet or machine.  There are many types of storage units and 
computer software programs to control and record storage and dispensing of medication.  This recommendation 
covers medication in unit dose dosage forms stocked in decentralized systems that are outside of the pharmacy, 
i.e., in a LTCF.  Prescribers, pharmacists and other medical staff determine the specific medications and quantities 
that are kept in the machines.  The patient’s medications are accessed and administered by a nurse in accordance 
with a medication or prescription order.  Frequently, initial access to medications is controlled by a pharmacist 
offsite who reviews and approves the orders. 
Medication waste is reduced because the medications are “dispensed” from the cabinet at the time of 
administration rather than from a patient specific multi-dose medication card.  In a survey by the BRP, nine states 
out of twenty-eight reported that they allow automated dispensing machines in LTCFs.  Experience in hospitals in 
Massachusetts and LTCFs in other states has shown that APSs can reduce medication waste.  However, the cost for 
computer software, the dispensing unit, conversion to new drug product packaging, training and new pharmacy 
technician duties should be documented and evaluated prior to recommending the use of APSs.   
 
Recommendation: The Task Force recommends the planning of a demonstration project of the effect of 
automated dispensing machines on reducing medication waste. 
Regulatory/Statutory Changes Required: None 
Status: Not being done now. 
Requires Involvement of Agencies Outside of Task Force:  U.S. Drug Enforcement Administration 
 
 
Return for Redispensing
 
Rather than being wasted by disposal, certain unused unit-dose packaged and other unused Schedule VI and over-
the-counter medications are returned to the dispensing pharmacy for the purpose of redispensing to patients or 
residents.   
 
Recommendation: The Task Force recommends the continuation of the return for redispensing of certain unused 
medications. 
Regulatory/Statutory Changes Required: None 
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Status: Being done now. 
Requires Involvement of Agencies Outside of Task Force: None 
 
 
Release Medications to Patient upon Discharge
 
Current DPH regulations permit medications to be released to patients or residents on discharge upon the written 
authorization of a physician, physician assistant or nurse practitioner.  DOC has a policy in place that allows 
inmates to take medications with them upon discharge.  DMA requests that when appropriate, medications are 
released with the patient on discharge.   
 
Recommendation: The Task Force recommends that medications be released with patients upon discharge when 
determined safe and appropriate and when authorized by a physician, physician assistant or nurse practitioner who 
are authorized to prescribe. 
Regulatory/Statutory Changes Required: None 
Status: Being done now. 
Requires Involvement of Agencies Outside of Task Force: None 
 
      
Demonstration Projects
 
One charge of Chapter 282 was to make recommendations that did not negatively affect other areas of the health 
care delivery system.  However a valid and credible analysis of the risks, costs and benefits of the implementation 
of any method is beyond the scope of this taskforce.  Therefore, demonstration projects would be needed to 
answer this charge and to ensure that cost savings measures do not come at the expense of patient safety or 
therapeutic effectiveness. 
One recommendation made by the group is to plan for demonstration projects of any methods adopted if they are 
not already in place.  Demonstration projects would be the starting point for data collection.  Demonstration 
projects may also be able to capture data that correlates to any impacts on other patient care activities such as 
medication administration.  
 
 
SUMMARY 
 
The Task Force sought information from the literature, other states, local experts, stakeholders and the mandated 
parties in Chapter 282 (b).  From surveys and the literature it was learned what actions other states are taking to 
control spending on pharmaceuticals.  A conference was held on October 28, 2002, and the Task Force used the 
suggestions put forth by the participants to develop an initial list of recommendations.  The final list of 
recommended methods was determined using the following criteria; (1) Has this method shown a positive impact 
on medication waste reduction in other states or patient care settings; (2) Would this method require start-up 
monies for equipment or staffing; (3) Would this method require a statutory or regulatory change; and (4) Can this 
method be employed now without negatively impacting the medication delivery system.  The recommended 
methods are: use of medical practice guidelines; optimization of prescription ordering; academic detailing; 
collaborative practice; use of formularies; therapeutic interchange; use of prior authorization; implementation of 
automated pharmacy systems; return for redispensing; and release of medication with patient upon discharge. 
Rigorous demonstration projects should be conducted to show the impact of the recommended methods on costs, 
patient care and the health care delivery system.   
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The Task Force finds that maximizing clinical effectiveness and operational efficiency, by following in part, in whole, 
or in combination the recommendations, will improve drug therapy patient outcomes and decrease medication 
waste.  Although no regulatory or statutory changes may be required to implement some of the recommendations, 
DPH, BRP and/or DMA will need to work with the health care community on guidelines or policies for safe and 
effective implementation of methods to reduce medication waste.  Furthermore, the three member agencies are 
interested in intra or interagency work to collect and analyze data that will show how the health care delivery 
system has been affected, positively or negatively.  The Task Force recognizes that some patients of residential or 
correctional facilities may require more costly drug therapy, individualized monitoring for side-effects or therapeutic 
effectiveness and reiterate that methods to reduce medication waste should not compromise patient health.   
As individual agencies and collaborators, the Task Force has seen here and from previous work that there is no 
single solution that can address medication waste.  In a health care system with limited resources, responsible 
parties will recognize the ever-closer relationship between how actions on behalf of individual patients affect the 
health of the community’s patients.   
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GLOSSARY 
Academic Detailing: Educational outreach, often by clinical pharmacists, to target less than optimal 
prescribing. 
Automated Pharmacy Systems: medication dispensing technology systems that perform operations or 
activities relative to the storage, packaging, dispensing or distribution of medications and that collect, control 
and maintain all transaction information.   
May be referred to as “automation,” or APS 
Collaborative Practice: A written agreement between a physician and a pharmacist to provide pharmaceutical 
care services within defined limits.   
Formulary: A list that limits the drug product choices available to treat specific patient populations. 
MassHealth: State provided health care for certain low- and medium- income people living in Massachusetts. 
Prior Authorization: Approval for use of a medication before it is dispensed.   
Return for Redispensing: The return of unused unit-dose packaged and certain other unused Schedule VI 
and over-the-counter medications to pharmacies for the purpose of redispensing to patients or residents.   
Therapeutic Interchange: The selection and use of one drug product in a therapeutic category when the 
multiple drug products in that therapeutic category are considered equivalent in terms of efficacy, safety and 
outcomes.  
Unit Dose: Unit-dose packaging means an individual drug product container, usually consisting of foil, molded 
plastic or laminate with indentations into which a single solid oral dosage form is placed, with any accompanying 
materials or components including labeling. Each individual container is fully identifiable and protects the 
integrity of the dosage form.   
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Attachment 1 
 
Chapter 282 of the Acts of 2002 
 
  AN ACT REDUCING MEDICATION WASTE IN CERTAIN LICENSED FACILITIES. 
 
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the 
same, as follows:  
 
SECTION 1. (a) The department of public health, in conjunction with the board of registration in pharmacy and 
the division of medical assistance, shall convene a taskforce to review and make recommendations on methods to 
reduce medication waste in facilities licensed by the departments of public health, mental health and corrections. 
The taskforce shall recommend such methods, based on its review, that are determined to be effective in reducing 
waste without imposing unreasonable costs on the health care delivery system. The taskforce's review shall 
address, but not be limited to, the following areas: (1) current technology, standards and reimbursement 
mechanisms for dispensing and distributing medications to facilities; (2) other states' requirements for limiting 
prescription drug waste and any cost savings realized; (3) the commonwealth's standards for the return and re-
dispensing of patient-specific schedule VI prescription drugs; and (4) possible incentive mechanisms to prevent the 
creation of prescription drug waste.  
(b) The taskforce shall consist of up to 2 representatives from each of the following offices: the department of 
public health, the board of registration in pharmacy and the division of medical assistance. The taskforce shall 
consult with representatives from the board of registration in nursing, the board of registration in medicine, the 
department of mental health, the department of corrections, and may consult with representatives from the 
following entities, as the taskforce deems necessary: the Massachusetts Society of Consultant Pharmacists, 
Massachusetts Extended Care Federation, Massachusetts Society of Health System Pharmacists, Massachusetts 
Medical Society, Massachusetts Nurses Association, Massachusetts Hospital Association, the Long-Term Care 
Pharmacy Alliance, the Home and Health Care Association of Massachusetts and other industry representatives and 
consultants.  
SECTION 2. The taskforce shall submit a report to the joint committee on health care and the house and senate 
committees on ways and means on or before September 30, 2002.  
Approved August 14, 2002.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attachment 2 
State Boards of Pharmacy 
 
 
                      Does your state 
currently allow 
automated 
dispensing devices 
(ADMs) to be used in 
LTCF? 
If yes, what schedules 
of prescription 
drugs/devices are 
allowed to be 
dispensed by the 
ADM? 
Are certified 
technicians allowed 
to stock the ADMs? 
Does your state 
allow pharmacy 
departments to be 
located in a LTCF?
Has your board 
adopted any new 
innovations in 
technology, 
equipment, or 
services resulting 
in cost effective 
reduction of waste 
in LTCF? 
How can I 
obtain the 
enabling  
regulation/pol
icy  (online or 
hardcopy)? 
Comments/additional 
information 
Missouri 
Contact:Kevin Kinkade 
yes C-II to C-VI yes yes no hardcopy sent  
Arizona 
Contact:None 
yes varies on track-record 
of applicant and 
policy/procedure 
submitted 
yes yes no upon request ADM approval 
depends on the 
submission of policy 
and procedure 
South Dakota 
Contact:Dennis M. Jones     
(605)362-2736 
yes C-II to C-V yes yes no Internet Must have pharmacy license to 
allow ADM 
Louisiana 
Contact:Malcolm Broussard 
(225)925-6481 
yes all schedules          no 
restriction 
yes yes no Internet  
Kentucky 
 Contact:Michael A. Mone 
yes all schedules          no 
restriction 
yes yes no Internet No regulation to prohibit the 
use of ADM 
Rhode Island 
Contact:Catherine Cordy     
(401)222-2840 
yes C-II to C-VI yes yes no upon request  
Oklahoma 
 Contact:None 
no n/a n/a no no   
Kansas 
   Contact:Susan Linn 
no n/a n/a no no   
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Delaware 
Contact:Dave Dryden          
(302)739-4798 
yes C-III to C-V          no 
C-VI in this state 
 yes   yes no Internet  Non-certified technicians can 
also restock ADM 
Utah          
Contact:None 
no n/a n/a no no   
Hawaii         
Contact:Lee Ann Teshima    
(808)586-2694 
no n/a n/a yes no   
Oregon      
Contact:Gary Schnabel 
(gary.a.schnabel@state.or.
us) 
yes not specified not specified yes no Internet There is no distinction 
between automated and 
manual system 
Tennessee 
Contact:Kendall Lynch 
no n/a n/a yes no  This topic was reviewed but 
the company never asked for 
the approval for ADD 
New Hampshire 
Contact:None 
no n/a n/a yes yes upon request medications dispensed may be 
returned to pharmacies for 
credit--   Ph 704.07 (b) (9) 
Pennsylvania 
Contact:Melanie 
Zimmerman        
 (717)783-7196 
no               
*not specifically 
addressed by the 
board 
n/a n/a yes no hardcopy sent The Board would issue the 
license, but the DPH regulates 
LTCF and would have to 
approve as well 
Minnesota      
Contact:none  
no n/a n/a yes            no   
Texas 
Contact:Steve Morse 
(512)305-8027 
yes C-II to C-VI yes yes            
* limited to 
community 
pharmacy 
yes hardcopy sent Meds may be returned to 
pharmacies for reuse provided 
that meds are in sealed 
tamper evident packaging and 
are unopened 
Idaho 
Contact:Jan Atkinson     
(208)334-2356 
yes C-II to C-V yes yes            yes upon request Allow return/reuse 
meds under restricted 
guidelines if facility is licensed 
by the Board  
*Assisted Living Facilities can 
not return meds b/c not 
licensed by the Board 
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Connecticut       
Contact:Michelle Sylvestre   
(860)713-6065 
no C-III to C-V and 
legend drugs 
yes yes             no upon request ADM is used for emergency 
stocks only—sec.210.70(1) 
and sec.210.250(d) 
Nevada        
Contact:Keith Macdonald 
(847)698-6227 
yes                 *  C-II to C-V yes yes            yes upon request new concept of ADM is to 
eliminate waste or return 
meds in dose packs to 
dispensing pharmacies for 
reuse 
Nebraska       
Contact:none  
no n/a n/a yes            
* if facility obtain a 
pharmacy license 
yes upon request medications dispensed may be 
returned to pharmacies for 
reuse--Sec.562.109 
Alabama       
Contact:Jerry Moore  
yes not specified yes yes no hardcopy sent  
North Carolina     
Contact:Steve Hudson      
(828)465-2324  
yes C-II to C-VI yes yes no hardcopy sent ADM is allow in LTCF provided 
that the site has a pharmacy 
permit 
* Non-certified technicians can 
restock ADM 
Georgia  
Contact:Laura Sturick  
no n/a n/a n/a no   
 
Created by:  Uyen Le, Pharm.D. Candidate 
 
The following is a brief summary of 24 surveyed State Pharmacy Boards: 
 
• 13 states allow ADM in LTCF with specific drug schedules and allow certified technicians to stock ADD. 
 ? AL, AZ, MO, SD, LA, KY, RI, DE, OR, TX, ID, NC, NV 
 ? In addition, DE and NC also allow non-certified technicians to stock ADD under the supervision of the licensed pharmacist 
 
• 11 states do not allow ADM in LTCF. ? CT, GA, HI, MN, NE, NH, KS, OK, PA, TN, UT 
 
• 1 state does not allow ADM in LTCF, but allow certified technicians to stock ADM in hospital facilities which is used as emergency stocks only. 
 ? CT 
 
• 19 states allow LTCF to locate pharmacy departments with in the facility                                                                                                                                                    
? AL, AZ, MO, SD, LA, KY, RI, DE, OR, TX, ID, NC, HI, MN, NH, NE, PA, TN without ADM use 
 
• 5 states allow return of medicines, under certain conditions, to the dispensing pharmacies for reuse and/or credit. ? ID, NE, NH, NV, 
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  Attachment 3      
 
DPH and DMA SURVEY 
Question: What medication management methods (listed) do you employ in long term care facilities, other residential (non-
acute care hospitals) facilities or prisons to prevent or decrease medication waste? 
Eighteen states responded: AK, CT, IA, ID, IN, KY, MA, MO, MN, ND, NV, PA, SC, UT, VA, WA, WI, WY 
FACILITY TYPE 
    
  
LTCF Other Residential  Prisons 
Automated Dispensing Systems
 
AK, NV(pending), 
SC, WA 
AK, SC, VA, WA  
Pharmacies in 
LTCFs’ 
AK, ND, SC, VA  ND 
Formularies 
 
IN, KY IN, KY IN, ND 
Return for  
Redispensing 
CT, ID, IN, KY, IA. MA, MN, MO, 
ND, SC, UT, VA, WA, WI 
 
KY, ND, SC  
Prior  
Authorization (PA) 
AK, ID, IN, IA, KY, MA, MN, MO, 
ND, PA, SC, UT, WA, WV, WY 
AK, ID, IN, IA, KY, MA, MN, MO, 
ND, SC, WA, WV, WY 
IN, WY 
Therapeutic 
Interchange 
AK, ID, MO,  ID, MO, WA  
 
 
 
 
M 
E 
T 
T 
H 
O 
D 
S 
Academic Detailing 
 
AK, ID, WA AK, ID, WA  
  Total Net Cost Savings Where Reported: Return for Redispensing: CT $360,000; MO$132,954 
        Prior Authorization:  MO (total for sites listed) $32,603,363  
                                        WV (for overall PA program) $14,000,000  
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Attachment 4 
DMA SURVEY 
What, if any, incentives does your state offer pharmacies and/or facilities for effectively for managing 
(preventing) medication waste? 
State Pharmacies? Annual Cost Savings Facilities? Annual Cost Savings 
Alaska None None None None 
Arkansas None None None None 
Connecticut 
$5.00 per Rx paid if savings 
to the state $360,000. +/- 
None positive; 
$30,000. Fine for 
failure to 
participate N/A 
Idaho None None None None 
Indiana 
They can retain the 
associated dispensing fee 
for the returned product N/A N/A N/A 
Iowa None None None None 
Kentucky N/A N/A N/A N/A 
Massachusetts N/A N/A N/A N/A 
Minnesota 
$0.30 for prescriptions 
dispensed to LTC facilities 
in unit dose packaging that 
the pharmacy packages in 
house. Unknown None   
Missouri None N/A None N/A 
Nevada 
Increased dispensing fee 
for u/d Unknown None   
North Carolina No regulations       
North Dakota 
Decision is up to the 
pharmacist/ First $10 need 
not be credited/ only cost 
of meds not fee is credited $36,000.00 
keeps patient 
happy, saves 
medication/ more 
money in budget 
to pay LTCF 
  
 
Ohio None None None None 
Oklahoma None None None None 
Pennsylvania None None None None 
South Carolina 
70-80% of all Medicaid 
LTCF beds are reimbursed 
at $9.00/ patient/day to the 
pharmacy provider.  
Savings accrue to the 
pharmacy provider.  ARM 
program. N/A 
The cost of most 
OTC (over the 
counter) items are 
included in the 
facilities' per diem 
rate and all cost 
saving accrue to 
the facility. N/A 
South Dakota None None None None 
Texas None None None None 
Utah None N/A None N/A 
Virginia 
Add on dispensing fee and 
package fees per unit dose Not Known N/A Not Known 
Washington None None 
OTC included in 
per diem rate for 
SNFs   
West Virginia None None None None 
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Attachment 5 
From the National Pharmaceutical Council, 
“Pharmaceutical Benefits Under State Medicaid Assistance Programs, Pharmacy Payment and Patient Cost Sharing” 
State Reimbursement Formula Dispensing Fee Co-payment 
Alabama AWP-10%; WAC+9.2% $5.40 $0.50 - $3.00 
Alaska AWP-5% 
$3.45 to $11.46 for 
instate pharmacies $2.00 
Arkansas AWP-14% for brand $5.51 per CFR $0.50 - $3.00 
California AWP-5% $4.05 $1.00 
Colorado AWP-11% OR WAC $4.00 B/$3.00, G/$0.75 
Connecticut AWP-12% $3.85 None 
Delaware AWP-12.9% $3.65 None 
DC AWP-10% $3.75 $1.00 
Florida AWP-13.25%; WAC+7% $4.23 - $4.73 None 
Georgia AWP-10% 
$4.63 + $0.50 for G or 
P 
G/P: $0.50, B/NP: $0.50 -
$3.00 
Hawaii AWP-10.5% $4.67 None 
Idaho AWP-12%, FUL, SMAC Lower of 
$4.94 or $5.54 if 
delivery is  5x per week 
to LTC None 
Illinois AWP-11% B/$4.00, G/$5.10 $1.00 
Indiana AWP-20% for Generic,  AWP-13.5% for Brand $4.90 $0.50 - $3.00 
Iowa AWP-10% $5.17 $1.00 
Kansas AWP-10%, IV AWP-50%,  blood AWP-30% $4.50 $2.00 
Kentucky AWP-12%  $4.51 
$1.00 for those not 
exempt 
Louisiana AWP-13.5%  (AWP-15% for chains) $5.77 $0.50 - $3.00 
Maine AWP-10% 
$3.35 (plus extra fees 
for compounding) $0.50 - $3.00 
Maryland Lower of: WAC+10%, direct+10%, AWP-10% $4.21 $1.00 
Massachusetts WAC + 6 or FULP or MULP or U&C $3.50 $2.00 
Michigan 
AWP-13.5%(1-4 stores), AWP-15.1% (5+ 
stores) $3.72 $1.00 
Minnesota AWP-9% $3.65 None 
Mississippi AWP-10% $4.91 $1.00 
Missouri AWP-10.43%, WAC+10% $4.09 
$0.50 - $2.00, $5.00 for 
some 1115 pop. 
Montana AWP-15% 
$4.70 for in state,  
$350 for out of state 
$1.00 to $5.00  with a 
monthly cap of $25 
Nebraska AWP-10% $3.84 - $5.05 $1.00 
Nevada AWP-15% $4.76 None 
New Hampshire AWP-12% $2.50 B/$1.00, G/$0.50 
New Jersey AWP-10%, WAC+30%,  AAC for injectables $3.73 - $4.07 None 
New Mexico 
Lesser of AWP-12.5%, Federal Upper Limit, 
State Maximum Allowed Cost, Dept of Justice 
AWP or Usual and Customary $3.65 
None (except CHIP and 
working disabled) $2.00
State Reimbursement Formula Dispensing Fee Co-payment 
New York AWP-10% B/$3.50, G/$4.50 B/$2.00, G/$0.50 
North Carolina 
lowest of: AWP-10%, State MAC, Federal MAC 
or u/c 
$4.00/Brand and 
$5.00/Generic 
$3.00/Brand and 
$1.00/Generic 
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North Dakota AWP-10% $4.60 
$3.00/ Brand None for 
Generic 
Ohio WAC+9% $3.70 None 
Oklahoma 
Lesser of EAC, FUL, or SMAC + $4.15 dispensing 
fee for Usual & Customary Max. $4.15 
Rx cost up to $29.99 = 
$1.00  Rx cost $30.00 
and over = $2.00 
Oregon AWP-13% 
Retail: $3.50, Inst./NF: 
$3.80 None 
Pennsylvania AWP-10% $4.00 $1.00 ($2.00 for GA) 
Rhode Island WAC+5% OP: $3.40, LTC: $2.85 None 
South Carolina AWP-10% $4.05 
$3.00 for those not 
exempt 
South Dakota AWP-10.5% 
$4.75 up to $5.55 for 
Unit Dose $2.00 
Tennessee       
Texas 
 Currently lower of AWP-15%  or WAC +12% 
(Proposed change to lower of AWP-16%, WAC 
+1% or WAC-12% on FUL and State MAC 
Drugs) 
Currently $5.27 
(Proposed $6.04 with 
implementation of 
changes noted above 
to reimbursement 
formula) 
Currently none (Proposed 
$.50 generic $3.00 
brand) 
Utah AWP-12% 
$3.90 - $4.40 (based 
on area) 
$1.00 Traditional, $2.00 
Non-Traditional 
Vermont AWP-11.9% $4.25 $1.00 - $2.00 
Virginia AWP-10.25% $4.25 
$2.00/Brand  
$1.00/Generic 
Washington AWP-14% 
$4.20 - $5.20  (based 
on annual # of Rx) None 
West Virginia 
EAC=AWP-12%, FUL or usual & customary, 
which ever is less 
$3.90 (plus extra $1.00 
for compounding) $0.50 - $2.00 
Wisconsin AWP-11.25% 
$4.88 (to a maximum 
$40.11) 
$1.00, max 
$5/recip/pharm/mo 
Wyoming AWP-11% $5.00 $2.00 
From the National Pharmaceutical Council, “Pharmaceutical Benefits Under State Medicaid Assistance Programs, Pharmacy Payment and 
Patient Cost Sharing” 
Legend: 
G =  Generic 
P =  Preferred 
B =  Brand 
NP =  Non preferred 
AWP =  Average Wholesale Price 
FUL =  Federal Upper Limit 
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Attachment 6 
 Medication Management Task Force October 28, 2002 
Conference Invitee and Participant List 
Last Name First Name Title Group 
Achin-Sullivan Nancy Executive Director MA Board of Registration in Medicine* 
Audet Adele Assistant Director MA Dept. Public Health 
Barr Judith Sc.D. 
Northeastern University, Bouve College of Health 
Sciences 
Bonanno Theresa Executive Director MA Board of Registration in Nursing* 
Brandt Lucinda  MA Division of Health Care Finance and Policy 
Buyse MaryLou M.D. MAHP 
Carrow Grant Director MA Dept. Public Health 
Cayer George R.Ph. Long Term Care Pharmacy Alliance* 
Chase Barbara  MassPRO 
Cinqueonce Carmelo Executive Director MA Pharmacists Assoc 
Cinqueonce Carmelo Executive Director MA Health Systems  Pharmacists* 
Coughlin MaryRose Director of Nurses MA County Jail Health Administrators Workgroup 
Crane Bob  PhARMA 
Daley Timothy  Sen. Chandler/ Health Care Committee 
Dell'Olio Louis Director  State Office of Pharmacy Services (DOC and DMH)*
DeLoach Charlene  Sen. Moore/ Health Care Committee 
Donatelli Bill R.Ph. MA Society of Consultant Pharmacists* 
Dreyer Paul Director  MA Dept. Public Health  
Feldman Stephen R.Ph. ICPS Group 
Fidyrch Mariellen Executive Director MA Sheriff's Association 
Gleason Richard Ed.D. MA Division of Professional Licensure 
Greenlaw Adam Research Analyst Joint Committee on Health Care 
Griswold Paula Executive Director MA Coalition for the Prevention of Medical Errors 
Heffernan Peter  MA Dept. of Corrections 
Herz Sue   
Hollander Ron President MA Hospital Assoc.* 
Jeffrey Paul 
Pharmacy Program 
Director MA Division of Medical Assistance 
Kelleher Patricia Executive Director MA Home and Healthcare Association 
Lapp Douglas  MA Division of Health Care Finance and Policy 
Lindberg Bette Executive Director MA Board of Registration Physicians Assts. 
MacIntrye Tim R.Ph. MA Dept. Public Health 
Megathlin Tony Investigator MA AG Office Medicaid Fraud Control Unit 
Monahan, Jr. Charles F. President Mass College Pharmacy 
Mulligan Mary Ann  MA Organization of Nurse Executives 
Nemmers Stephen Executive Director 
MA Board of Registration of Nursing Home 
Administrators 
O'Reilly Elaine  MA Assoc.of Physicians Assistants 
Paone Robert Professor MA College of Pharmacy 
Pinkham Julie Executive Director MA Nurses Assoc.* 
Ryder William Regulatory Affairs MA Medical Society* 
Sandberg Michael   
Sevier Rita 
Deputy Director of 
Clinical Projects MA Division of Medical Assistance 
Soong Sharon  Division Health Care Finance and Policy 
Sudders Mary Lou Commissioner MA Dept. Mental Health 
Thornhill  Gisele M.D. MA League of Community Health Centers 
Wheeler Claire  MA Extended Care Fed.* 
Young Charles Executive Director MA Board of Registration in Pharmacy 
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Last Name First Name Title Group 
  Central Office MA Dept Mental Retardation 
   Home & Health Care Association of MA* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attachment 7 
GENERAL LAWS OF MASSACHUSETTS 
 
TITLE XVI. 
PUBLIC HEALTH.  
 
CHAPTER 111. PUBLIC HEALTH.  
Chapter 111: Section 25I. Unused medication; return by health care facilities. 
Section 25I. The commissioner by rules and regulations may provide that either a resident or consultant pharmacist 
in a health care facility may return to the pharmacy from which it was purchased any unused medication provided 
that such medication is sealed in unopened, individually packaged units and within the recommended period of 
shelf life, and provided that such medication is not a schedule I or II controlled substance as defined in chapter 
ninety-four C. Such rules and regulations shall permit the pharmacy to which such medication is returned to 
restock and redistribute such medication, and shall be required to reimburse or credit the purchaser for any such 
returned medication. 
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Attacment 8 
 
Massachusetts Department of Public Health 
 
Division of Health Care Quality and Drug Control Program 
 
Guidelines for Use of Unit-Dose Packaging for the Management and 
Administration of Pharmaceuticals in Long Term Care Facilities 
 
  In accordance with Department of Public Health (Department) regulations at 105 CMR 150.000 et 
seq. and 105 CMR 700.000 et seq., long term care facilities (facilities) may use unit-dose packaging for 
management and administration of  pharmaceuticals in accordance with the following guidelines. 
 
 
 Definition(s) 
 
  Unit-dose packaging means an individual drug product container, usually consisting of foil, 
 molded plastic or laminate with indentations into which a single solid oral dosage form is placed, 
 with any accompanying materials or components including labeling. Each individual container 
 is fully identifiable and protects the integrity of the dosage form. 
 
 Guidelines 
 
  1.  Written policies and procedures must be developed and implemented that describe 
   the procurement, administration, storage, security, disposal and record-keeping 
   necessary to assure accountability throughout the system, prevent medication 
   errors, impede drug diversion and facilitate the recall of prescription drug products. 
 
  2.  Policies must include the manner in which provisions for alternate deliveries will be 
   made in the event of an emergency situation (such as daily delivery not possible), 
   new admissions to the facility or a patient or resident choosing an alternate 
   pharmacy provider. 
 
  3.  Policies and procedures must comply with all applicable state and federal laws.  The 
Department does not require a waiver or advance     approval for use of unit-dose 
packaging. 
    
 
  4.  The policies and procedures must be approved by the facility's administration, 
   nursing and medical staffs. 
 
  5.  Appropriate training must be provided to the nursing staff as part of orientation and 
whenever significant system changes are made. 
 
  6.  The system must be periodically evaluated as part of the facility's quality 
   assurance/continuous quality improvement program. 
 
 
 Additional Information 
 
  This policy only covers utilization of unit dose packaging for medication management and 
 administration. There are separate requirements for the implementation of a system of return 
 for redispensing of unit-dose medications. 
 
  There are additional requirements that apply to the use of automated dispensing  machines in long 
term care facilities1. 
  
 
 1 Department of Public Health, Circular Letter DHCQ 3-98-380. 
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Attachment 9 
Massachusetts Department of Public Health 
 
Division of Health Care Quality 
and 
Drug Control Program 
 
Policy on Return for Redispensing of Medications from Long Term Care Facilities 
 
 Background 
 
  In accordance with M.G.L. c. 111, §25I, the Department of Public Health (Department), 
 permits long term care facilities (LTCFs) licensed by the Department to return unused unit-dose 
 packaged1 and certain other unused Schedule VI2 and over-the-counter medications to 
 pharmacies for the purpose of redispensing to patients or residents. Department policy also 
 permits LTCFs to utilize a unit-dose packaging for management and administration of 
 pharmaceuticals to patients or residents.3
 
  The Department, working with the Board of Registration in Pharmacy4, has determined 
 that the return for redispensing of unit-dose packaged medications can be a safe and effective 
 method of pharmaceutical distribution. The return for redispensing of unit-dose packaged 
 medications may contribute to the reduction of medication waste.5 
 
  Department regulations and this policy govern only the return for redispensing of 
 medications from LTCFs to pharmacies. Regulations of the Board of Registration in Pharmacy 
 govern the receipt and redispensing of such returned medications. 
 
 
 
 1 Unit-dose packaging means an individual drug product container, usually consisting of foil, molded plastic or laminate with 
indentations into which a single solid oral dosage form is placed, with any accompanying materials or components including 
labeling.  Each individual container is fully identifiable and protects the integrity of the dosage form.  Labeling is in accordance with 
United States Pharmacopoeia standards compendia and federal and state law.  For purposes of this policy traditional "bingo cards" 
or“bubble packs” are considered an assemblage of multiple, unlabeled, single doses and are not considered to be unit-dose packaging. 
 
 
 2 Schedule VI medications refers to all prescription medications that are not in federal Schedules II - V. 
 
 3 Department of Public Health Guidelines for Use of Unit-Dose Packaging for the Management and Administration of 
 Pharmaceuticals in Long Term Care Facilities. 
 
 4 Board of Registration in Pharmacy, 239 Causeway St., Boston 02114. 
 
 5 Department of Public Health Report, May 31, 1996, Special Project: Dispensing of Unit Dose Medications in LTCFs. 
 
 
 
 
 
 Requirements 
 
 1)  The LTCF must have a written policy regarding the return for redispensing of Schedule 
  VI and over-the-counter medications. The policy must address patient or resident safety 
  issues including but not limited to: 
 
  A) ensuring the integrity of drugs subjected to extended and repeated handling, storage 
      and transportation; 
  B) ensuring dispensers, repackagers and ultimate users can be identified and notified in   
     the event of a recall; 
  C) minimizing opportunities for tampering and diversion; and 
  D) ensuring that all medications are stored in accordance with the standards of the United 
       States Pharmacopoeia (USP); 
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 2) Drug products that may be returned are limited to: 
 
    A) intact, solid oral dosage forms, in unit-dose packaging and packaged as follows: 
          i) by the original manufacturer; or 
                   ii) by the pharmacy in accordance with industry standards; 
               B) ampules; 
               C) suppositories; 
               D) parenteral medications in single-dose sealed containers; and 
               E) medications in multi-dose sealed containers6, that are dispensed pursuant to an order 
                    for an individual patient or resident and from which no doses have been withdrawn; 
 
 3) The following must be indicated clearly on each individual unit: 
 
       A) if a single active ingredient, the established name of the drug and the quantity of the 
                active ingredient per dosage unit; 
                B) if a combination drug, the established name and quantity of each active ingredient per 
                dosage unit; 
                C) lot or control number; 
                D) expiration or beyond use date; 
                E) NDC number or equivalent information; and 
                F) any special storage and handling instructions required by USP standards or state or 
                federal law; 
 
 4) The following drug products may not be returned to a pharmacy for redispensing: 
 
A) compounded or reconstituted drugs; 
B) drugs that require refrigeration; 
C) drugs that are adulterated or misbranded; 
D) drugs which have had their integrity, packaging or labeling compromised (e.g., through 
environmental damage such as water damage, crushing, a broken seal, a torn or marked label); and 
E) drugs designated as Schedule II - V controlled substances in accordance with M.G.L. c. 94C, §3. 
 
 
 
 
 
 5) Medications must be returned to the pharmacy (including location) from which they were 
     originally dispensed; 
 
 6) Drug products must be returned within 30 days of discontinuation of use by a patient or 
     resident; 
 
 7) Drug products must be returned no less than 90 days prior to the beyond use date or 
     expiration date, whichever is earlier; 
 
 8) The LTCF must establish tracking and recordkeeping systems for returned medications: 
 
    A) Records must include: 
         i) the date returned to the pharmacy; 
                   ii) prescription number under which the unused medication was originally dispensed; 
                   iii) identity and strength of drug product; 
              B) This information must be made available to the Department upon request; and 
              C) These records shall be kept on file for a period of two years; and 
 
 9) In accordance with M.G.L. c. 111, §25I, the pharmacy to which such medication is returned 
     shall reimburse or credit the purchaser for any such returned medication. 
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Attachment 10 
 
 
POLICY Number PH - 2002 - 01 
Policy on Return for Redispensing of Medications from Long Term Care Facilities 
Interpretation of M.G.L. c. 94C, § 18(d) 
re: Issuance of Prescription by Practitioner or Physician
According to Board of Registration in Pharmacy (Board) regulations (247 CMR); specifically,  
9.01: Code of Professional Conduct for Registered Pharmacists, Pharmacies and Pharmacy 
Departments
(1) A registered pharmacist shall at all times conduct professional activities in conformity with federal, state 
and municipal laws, ordinances and/or regulations, including the regulations of the Board. 
(2) A pharmacist shall not dispense drugs, devices, or other substances in a manner which is intended, 
either directly or indirectly, to circumvent the law. 
(3) A pharmacist shall observe the standards of the current United States Pharmacopoeia (USP). 
(4) Unless otherwise permitted by law, a pharmacist shall not redispense any medication which has been 
previously dispensed. 
In accordance with the authority granted by M.G.L. c. 111, s. 25I, the Department of Public Health (DPH) has 
adopted a Policy on Return for Redispensing of Medications from Long Term Care Facilities permitting 
long term care facilities (LTCFs) licensed by DPH to return certain unused unit-dose packaged and certain other 
unused Schedule VI and over-the-counter medications to pharmacies for the purpose of redispensing to patients. 
This DPH policy permits LTCFs to utilize unit-dose packaging for the management and administration of 
pharmaceuticals to patients. 
In accordance with 247 CMR 9.01(4), the Board has voted to adopt the DPH’s Policy on Return for 
Redispensing of Medications from Long Term Care Facilities (attached in PDF) and permit the redispensing 
of certain medications from LTCFs in accordance with DPH policy requirements; provided that the pharmacist 
redispensing any previously dispensed prescription or non-prescription drug product has determined, 
using proper professional judgment, that the drug meets USP standards compendia for dispensing. 
Additionally, to redispense permitted medications, the pharmacy will be required to have a written policy 
regarding the return for redispensing of Schedule VI and over-the-counter medications returned from LTCFs. The 
written policy must address patient safety issues including, but not limited to: 
1. Ensuring that the drugs returned were originally dispensed by the same pharmacy;  
2. Ensuring that a pharmacist is in control of the redispensing process and has verified each order before 
redispensing;  
3. Ensuring dispensers, repackagers and ultimate users can be identified and notified in the event of a recall;  
4. Minimizing opportunities for tampering and diversion;  
5. Verifying the drugs are not expired and have a minimum of three (3) months/ninety (90) days remaining to 
the beyond use date or expiration date, whichever is earlier;  
6. Requiring that the pharmacist obtain assurances from a responsible person in charge of the drugs that the 
drugs have been stored in accordance with the manufacturer's recommendations and current United States 
Pharmacopoeia standards compendia;  
7. Disallowing the return or redispensing of any temperature sensitive drug or any drug requiring 
refrigeration;  
8. Disallowing the return or redispensing of any compounded or reconstituted medication;  
9. Disallowing the return or redispensing of any medication which appears to be adulterated or misbranded;  
10. Disallowing the return or reuse of any drug designated as Schedule II-V controlled substances, in 
accordance with M.G.L. c. 94C, s. 3;  
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11. Disallowing the return or reuse of drugs which may have had their integrity, packaging or labeling 
compromised (e.g., through environmental damage such as water damage, crushing, a broken seal, a torn 
or marked label);  
12. Requiring the maintenance of a repackaging record, including the name, strength, lot number, quantity, 
manufacturer and/or distributor information, date of repackaging, number of packages prepared, number 
of dosage units in each package, signature of person performing the repackaging, signature of the 
supervising pharmacist, and such other identifying marks as may be added by the pharmacy for 
recordkeeping purposes;  
13. Requiring the maintenance of a packing manifest for each prescription drug returned by the facility to the 
pharmacy, to be readily retrievable and maintained at the dispensing pharmacy for a minimum of seven 
years; and,  
14. Requiring that a pharmacist has determined, using proper professional judgment, that all such drugs are 
appropriate for redispensing.  
Board Adoption Date: March 26, 2002 
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Commonwealth of Massachusetts 
Executive Office of Health and Human Services 
Division of Medical Assistance 
600 Washington Street 
Boston, MA  02111 
www.mass.gov/dma 
MASSHEALTH 
TRANSMITTAL LETTER NF-43   
June 2002 
 
 TO: Nursing Facilities Participating in MassHealth 
 
FROM: Wendy E. Warring, Commissioner 
 
 RE: Nursing Facility Manual (Unit Dose Return for Certain Drugs) 
 
 
In an effort to reduce pharmaceutical waste in nursing facilities, the Division has developed a unit-dose 
return requirement of certain drugs for nursing facilities and pharmacies.  This letter transmits revisions 
to the nursing facility regulations.  Under these regulations, the nursing facility must return to the 
dispensing pharmacy certain unused unit-dose-packaged drugs that were dispensed to MassHealth 
members.   
 
These new requirements apply only to the eight drugs listed in Appendix F of the Nursing Facility 
Manual.  The Division may update this appendix to include additional drugs at a later date.  Nursing 
facilities should refer to 130 CMR 456.621 for specific requirements related to returning unit-dose-
packaged drugs. 
 
Department of Public Health Guidelines 
The Department of Public Health has issued two documents about unit-dose dispensing and return: 
• Policy on Return for Redispensing of Medications from Long Term Care Facilities 
• Guidelines for Use of Unit-Dose Packaging for the Management and Administration of 
Pharmaceuticals in Long Term Care Facilities. 
 
Nursing facilities must adhere to these guidelines when returning drugs in unit-dose packaging. A copy of 
each of these documents is included with this transmittal letter.   
 
Best Practices 
The Division, in concert with nursing facility and pharmacy stakeholders, has also prepared “Best Practices” guidelines.  These guidelines advise 
nursing facilities and pharmacies on how to best manage the unit-dose return policy described in the attached regulations. The “Best Practices” 
guidelines are also included with this mailing for your information.   
 
Questions or Comments 
Nursing facilities may e-mail comments or questions about this new policy to medreturn@nt.dma.state.ma.us.  All questions submitted through 
this electronic mailbox will be summarized and presented to the Massachusetts Extended Care Federation Unit-Dose Return and Redispense 
Policy Workgroup.  This workgroup will provide responses and updates to the nursing facility industry through newsletters, the Internet, and 
existing workgroups.  An information sheet about submitting inquiries through this electronic mailbox is also included with this letter. 
 
These regulations are effective July 1, 2002. 
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Commonwealth of Massachusetts 
Executive Office of Health and Human Services 
Division of Medical Assistance 
600 Washington Street 
Boston, MA  02111 
www.mass.gov/dma 
 
MASSHEALTH 
TRANSMITTAL LETTER PHM-45   
June 2002 
TO:Pharmacies Participating in MassHealth 
 
FROM: Wendy E. Warring, Commissioner 
 
 RE: Pharmacy Manual (Unit Dose Return for Certain Drugs) 
 
 
In an effort to reduce pharmaceutical waste in nursing facilities, the Division has developed a unit-dose-
dispensing and return requirement of certain drugs for pharmacies and nursing facilities.  This letter 
transmits revisions to the pharmacy regulations.  Under these regulations, the pharmacy must fill 
prescriptions for certain drugs in unit-dose packaging when they are dispensed to MassHealth members 
residing in a skilled nursing facility.  The pharmacy must also credit to the Division amounts paid by the 
Division for certain unused unit-dose-packaged drugs that have been returned by the nursing facility.   
 
These new requirements apply only to the eight drugs listed in Appendix D of the Pharmacy Manual.  
The Division may update this appendix to include additional drugs at a later date.  Pharmacies should 
refer to 130 CMR 406.446 for specific requirements related to the dispensing and crediting of returned 
unit-dose-packaged drugs. 
 
The Division will pay the pharmacy a unit-dose return fee in accordance with the rate established by the 
Massachusetts Division of Health Care Finance and Policy (DHCFP), for each returned prescription 
credited to the Division.  This rate will be adopted in early July, and will be effective July 1, 2002.  The 
Division is recommending the amount of the return fee to be $5 per prescription.  Providers may check 
the DHCFP Web site at www.mass.gov/dhcfp in early July to confirm the amount of the adopted fee.  
 
Updated Billing Guides 
Under separate cover, pharmacies will receive updated billing guides from ACS, the Division’s Pharmacy 
On-line Processing vendor, that will describe how to credit the amount of the returned drugs to the 
Division and receive the return fee.  Once the returned drugs are credited to the Division, the pharmacy 
may redispense the drugs in accordance with guidelines established by the Department of Public Health.   
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DOC Medication Management 
Tablets Returned 
 
Medications for Each Month 
(All Strengths Included) 
Dollar Total February - October 2002 $179,060.57 
 
Break out: 
February March April May June July August  September October 
Lamivudine/ 
Zidovudine 
Lamivudine/ 
Zidovudine 
Abacavir/Lama
vudine/ 
Zodovudine 
Abacavir/Lama
vudine/ 
Zodovudine 
Citalopram Citalopram Citalopram Bupropion SR Bupropion SR 
Gabapentim  
Neurontin 
 
Gabapentim 
Neurontin 
 
Efavirenz Efavirenz Gabapentim 
Neurontin 
 
Gabapentim 
Neurontin 
 
Gabapentim 
Neurontin 
 
Citalopram Citalopram 
Nelfinavir Nelfinavir Gabapentim 
Neuronti 
Gabapentim 
Neurontin 
Olanzapine 
Zyprexa 
Olanzapine 
Zyprexa 
Olanzapine 
Zyprexa 
Divalproex 
Depakote ER 
Divalproex 
Depakote ER 
Olanzapine 
Zyprexa 
Olanzapine 
Zyprexa 
Lamivudine/ 
Zidovudine 
Lamivudine/ 
Zidovudine 
Paroxetine 
Paxil 
Paroxetine 
Paxil 
Paroxetine 
Paxil 
Gabapentin 
Neurontin 
Gabapentin 
Neurontin 
Paroxetine 
Paxil 
Paroxetine 
Paxil 
Nelfinavir Nelfinavir Quetiapine Quetiapine Quetiapine Mirtazapine 
Remeron 
Mirtazapine 
Remeron 
Risperidone 
Risperdal 
Risperidone 
Risperdal 
Olanzapine 
Zyprexa 
Olanzapine  
Zyprexa 
Risperidone 
Risperdal 
Risperidone 
Risperdal 
Risperidone 
Risperdal 
Olanzapine 
Zyprexa 
Olanzapine 
Zyprexa 
Sertraline 
Zoloft 
Sertraline 
Zoloft 
Paroxetine 
Paxil 
Paroxetine 
Paxil 
 
Sertraline 
Zoloft 
Sertraline 
Zoloft 
Sertraline 
Zoloft 
Paroxetine 
Paxil 
Paroxetine 
Paxil 
Stavudine Stavudine Risperidone  
Risperdal 
Risperidone  
Risperdal 
Bupropion SR Bupropion SR Bupropion SR Quetiapine Quetiapine 
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February March April May June July August  September October 
  Sertraline 
Zoloft 
Sertraline 
Zoloft 
   Risperidone 
Risperdal 
Risperidone 
Risperdal 
  Stavudine Stavudine    Sertraline 
Zoloft 
Sertraline 
Zoloft 
       To
e 
piramat Topiramate 
       Venlafaxine Venlafaxine 
 
$12,839.14 
 
$33,493.74 
 
$21,245.86 
 
$14,999.82 
 
$10,423.40 
 
$21,990.07 
 
$15,545.44 
 
$19,265.80 
 
$29,257.29 
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About the National Guideline Clearinghouse™ (NGC) 
The National Guideline Clearinghouse™ (NGC) is a comprehensive database of evidence-based 
clinical practice guidelines and related documents produced by the Agency for Healthcare Research 
and Quality (AHRQ) (formerly the Agency for Health Care Policy and Research [AHCPR]), in 
partnership with the American Medical Association (AMA) and the American Association of Health 
Plans (AAHP). 
The NGC mission is to provide physicians, nurses, and other health professionals, health care 
providers, health plans, integrated delivery systems, purchasers and others an accessible 
mechanism for obtaining objective, detailed information on clinical practice guidelines and to 
further their dissemination, implementation and use. 
Key components of NGC include:  
• Structured abstracts (summaries) about the guideline and its development;  
• A utility for comparing attributes of two or more guidelines in a side-by-side comparison;  
• Syntheses of guidelines covering similar topics, highlighting areas of similarity and 
difference;  
• Links to full-text guidelines, where available, and/or ordering information for print copies;  
• An electronic forum, NGC-L for exchanging information on clinical practice guidelines, their 
development, implementation and use;  
• Annotated bibliographies on guideline development methodology, implementation, and 
use.  
NGC Disclaimer Statement
NGC Credits/Technical Information
  
  About NGC     NGC Resources     Help     What's New     Contact NGC     Site Map      
Home     Non-Frames/Text Only Site     Accessibility      
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